China Resources Shuanghe acquired a 38.75% stake in Dongying Tiandong Pharmaceuticals

On December 17, China Resources Shuanghe announced that, in accordance with the company's overall strategic plan, in order to further enrich the cardiovascular anticoagulant field products, access to anticoagulant field technology platform, the company used its own funds to acquire a 38.75 percent stake in Dongying Tiandong Pharmaceutical Co., Ltd., the purchase price of 341 million yuan.
the management of the company is responsible for organizing and implementing the equity acquisition project related work.
Dongying Tiandong Pharmaceutical Co., Ltd. was established in 1992, is engaged in professional research and development and production and marketing of heparin, low-molecular heparin series of anticoagulant drugs pharmaceutical companies.
raw materials have been through the European Union EDQM and the United States FDA on-site audit, products in addition to domestic sales, sold to Europe and the United States and other dozens of countries and regions.
the enterprise registered capital of 407 million yuan, for high-tech enterprises, the main products are heparin sodium raw materials, inoheparin sodium raw materials, inoheparin sodium injection.
is mainly used clinically for thromboembolism diseases, myocardial infarction, cardiovascular surgery, cardiac catheter examination, in vitro circulation, hemodialysis, etc.
。